191results about How to "Maximize efficacy" patented technology

Devices, systems and methods by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably in the carotid sinus. A mapping method permits the baroreceptor activation device to be precisely located to maximize therapeutic efficacy.

Devices and methods for utilizing electromagnetic radiation and other forms of energy to treat a volume of tissue at depth are described. In one aspect, a device modulates the flux incident on surface tissue to control and vary the depth in the tissue at which an effective dose of radiant energy is delivered and, thereby, treat a specific volume of tissue. The methods and devices disclosed are used to perform various treatments, including treatments to relieve pain and promote healing of tissue.

The present invention is a system for providing baroreceptor stimulation comprising, a sensor to sense a physiologic parameter and provide a signal indicative of the physiologic parameter, a baroreceptor activation device, which includes, a pulse generator to intermittently generate a stimulation signal to provide baroreceptor stimulation for a baroreflex therapy, and a control system to adjust the stimulation signal based on the signal indicative of the physiologic parameter such that the stimulation signal provides a desired baroreceptor stimulation corresponding to a desired physiologic parameter.

Disclosed are probabilistic approaches to patient evaluation, warning and treatment of a neurological disorder. Disclosed techniques estimate probability distribution functions or cumulative distribution functions, determined by relying on representative historical profiles, comprising information in short and/or long timescales obtained at times that may be intermittent or temporally discontinuous from each other or from other events of interest. The patient may thereby be treated based on the determined probability information.

A method is provided for treating respiration conditions of a patient. The method comprises monitoring or measuring a respiration parameter indicative of a need to modify activity of a baroreflex system of the patient, and controlling a baroreceptor activation device to cause or modify activation of a baroreflex response of the patient in response to the monitoring or measuring of the respiration parameter.

A method for providing localized heating of the dermal layers of skin of a patient, using energy in the form of a group of pulses having defined parameters in a controlled manner. This method preferably uses an optical delivery system to deliver pulsed energy to a specific spot of skin so that targeted layers of the affected skin are heated to a desired temperature range. The temperature range is optimally selected to maximize treatment efficacy while minimizing pain to the patient. Example applications include reducing wrinkles, acne, hair, scar tissue, warts, and promoting wound healing. In this method, the temperature of the selected locus rises quickly to the desired temperature range, then is maintained within a controlled range with a relatively flat temperature profile. The method maintains the temperature by controlling one or more of a pulse energy intensity, pulse width, and pulse frequency or time delay between pulses.

A system and method for disinfecting hard surfaces in an area such as a hospital room including a light source emitting UV light and a reflector mounted behind the light source for concentrating and directing the light toward a target. The light source and reflector rotate to direct the concentrated beam around a room, thereby making more efficient use of the energy being emitted.

Targeted therapeutic delivery systems comprising specially-designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro are detailed. Nanocarriers comprised substantially of dendritic biopolymers and other species and compounds; are used to treat a variety of diseases in humans and other species, such as cancer, opthalmological, pulmonary, urinary or other pathologies. Methods for preparing the targeted therapeutic delivery systems are also embodied, which comprise processing a solution comprising biopolymers or other species and components, with or without targeting moieties, adding said biopolymers and other compounds to a solution containing one or more therapeutic agents, stabilizing or not stabilizing said nanocarriers, adding one or more contrast agents, resulting in a targeted therapeutic delivery system. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules.

The present invention provides pharmacological compounds including an effector moiety conjugated to an binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

A container (22) includes a shell (24) made from a polymer, for example PET, and incorporating a catalyst, for example a palladium catalyst. A closure (40) incorporates a plug which includes a source of hydrogen, for example a hydride. In use, with container (22) including a beverage and closure (40) in position, the headspace in the container will be saturated with water vapor. This vapor contacts the hydride associated with plug (42) and as a result the hydride produces molecular hydrogen which migrates into the polymer matrix of shell (24) and combines with oxygen which may have entered the container through its permeable walls. A reaction between the hydrogen and oxygen takes place, catalysed by the catalyst, and water is produced. Thus, oxygen which may ingress the container is scavenged and the contents of the container are protected from oxidation.

Methods and systems for developing and bio-refining or processing biomass feedstocks into a spectrum of bio-based products which can be used as a substitute for fossil oil derivatives in various types of product manufacturing processes and/or the production of bio-energy are disclosed. In addition, methods and systems for identifying, measuring and controlling key parameters in relation to specific biomass developing processes and bio-refining processes so as to maximize the efficiency and efficacy of such processes while standardizing the underlying parameters to facilitate and enhance large-scale production of bio-based products and/or bio-energy are disclosed.

A magnetic bearing for centering a first body, which is mobile in tilting, relative to a second body includes:a hollow outer part at least part of which is made from a ferromagnetic material and which is attached to the first body and which has an inside surface whose shape is a portion of a sphere,an inner part which is attached to the second body and which includes two separate members which are separated by a space and which each include a plurality of (at least three) ferromagnetic areas which are offset angularly about the reference axis, which each define in conjunction with the inside surface of the hollow outer part two air-gaps offset relative to the reference axis and which are each provided with a specific winding adapted to generate magnetic flux lines closing across the two air-gaps, andan excitation circuit for selectively applying excitation currents to the windings.

The present invention concerns the treatment of tumours. In particular the invention concerns the combination of agents which are adapted to increase B7-H3 and agents which are adapted to decrease or inhibit one or more HIFs. In a preferred embodiment, a vector adapted to express B7-H3 is administered along with antisense HIF.

The present disclosure provides a method for enhancing the anti-tumor efficacy of an Fc fusion protein which binds specifically to a target, e.g., a co-inhibitory or co-stimulatory receptor of ligand, on a T cell in a subject afflicted with a cancer or a disease caused by an infectious agent and alters the activity of the immunomodulatory target, thereby potentiating an endogenous immune response against cells of the cancer or the infectious agent, wherein the method comprises selecting, designing or modifying the Fc region of the Fc fusion protein so as to enhance the binding of said Fc region to an activating Fc receptor (FcR). The disclosure also provides an Fc fusion protein produced by said method which has an enhanced ability to potentiate an endogenous immune response against cells of a cancer or an infectious agent in a subject. The disclosure further provides a method for treating a subject which comprises administering to the subject a therapeutically effective amount of an Fc fusion protein, wherein the Fc region of the Fc fusion protein has been selected, designed or modified so as to increase the binding of said Fc region to an activating FcR.

The invention discloses fresh aloe juice gel, which comprises the following components in percentage by weight: 80 to 99 percent of organic fresh aloe juice, 0 to 5 percent of portulaca oleracea extract, 0 to 2 percent of hamamelis virginiana extract, 0 to 1 percent of capryloyl glycine, 0 to 1 percent of yellowish sophora root extract, 0 to 5 percent of beta-glucanase, 0 to 0.2 percent of hyaluronic acid, 0 to 0.3 percent of allantoin, 0 to 2 percent of panthenol, 0 to 10 percent of polyol, 0 to 1 percent of pyridoxine, 0 to 0.8 percent of nicotinamide, 0 to 0.1 percent of menthyl lactate, 0 to 0.1 percent of rosemary essential oil, 0.5 to 1 percent of carbomer, 0.4 to 0.8 percent of a preservative, 0.05 to 0.1 percent of EDTA-2Na, 0.05 to 1 percent of aminomethyl propanol and 0 to 0.2 percent of PEG-40 hydrogenated castor oil. The invention further discloses a preparation method and application of the fresh aloe juice gel. According to the fresh aloe juice gel, the problem that aloe polysaccharide of fresh aloe juice in conventional fresh aloe juice gel is easily degraded by a part of own biological enzymes and thermally degraded to reduce bioactivity of aloes is solved, the fresh aloe juice gel contains rich fresh aloe components, and the quality stability of the product can be maintained for more than 3 years.

This invention features methods of identifying genetic alterations that can modulate cancer cells' sensitivity to an anti-cancer drug. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy.

An acoustic crosstalk canceller is determined for an asymmetric audio playback device, by determining a transfer function of an acoustic stereo playback path having asymmetries defined by speakers of the playback device. The transfer function is inverted to determine an inverse transfer function. The inverse transfer function is regularised by applying frequency dependent regularisation parameters to obtain an acoustic crosstalk canceller. Also, the inverse transfer function could be regularised for symmetric playback paths by applying aggregated frequency dependent regularisation parameters to obtain an acoustic crosstalk canceller without band branching.

Disclosed are embodiments of a containment device having a flexible first layer and a flexible second layer sealed together to form a hermetically sealed reservoir. The surface area of contact between the first and the second layers can define a frame about the perimeter of the reservoir. The containment device can also include a porous pad located within the reservoir, and a liquid control solution configured to mimic a physiological fluid contained within the porous pad within the reservoir. The containment device can include a third flexible layer presenting a liquid holding surface for a user. A portion of the first and/or second layers can function as a frangible seal that is configured to be torn away by a user.